Familial Hyperinsulinism

Watchlist

(log in to enable)

Retrieved

2021-01-18

Source

Gene_reviews

Trials

—

Genes

KCNJ11, ABCC8, GCK, FOXA2, HADH, HNF4A, GLUD1, HNF1A, INSR, UCP2, SLC16A1, MEN1, PDX1, NEUROD1, CDKN1A, PAX4, INS, KLF11, MPI, BLK, CEL, CDKN2C, CDKN1B, MAFA, CDKN2B, APPL1, SST, GCG, MTOR, NSD1

KCNJ11, ABCC8, GCK, FOXA2, HADH, HNF4A, GLUD1, HNF1A, INSR, UCP2, SLC16A1, MEN1, PDX1, NEUROD1, CDKN1A, PAX4, INS, KLF11, MPI, BLK, CEL, CDKN2C, CDKN1B, MAFA, CDKN2B, APPL1, SST, GCG, MTOR, NSD1, PGM1, HAO2, MAP4K3, PDHX, KDM6A, MCTS1, IQGAP1, NES, CIB2, FGF21, MED25, SAR1A, HAO1, MCAT, NHS, TRPC4, GLP1R, CDKN1C, CMA1, DDC, DPP4, EHHADH, EMP1, HSD17B10, SKIL, HRAS, IGF1, LEP, PCNA, PMM2, RIT2, IH

Drugs

Dasiglucagon, Exendin-(9-39), Glucagon

Dasiglucagon, Exendin-(9-39), Glucagon, Glucagon analogue linked to a human immunoglobulin Fc fragment, Glucagon infusion, Recombinant human monoclonal antibody to insulin receptor

Interested in hearing about new therapies?

Summary

The purpose of this overview is to increase the awareness of clinicians regarding familial hyperinsulinism (referred to as FHI in this GeneReview) and its genetic causes and management.

The following are the goals of this overview.

Goal 1.

Describe the clinical characteristics of FHI.

Goal 2.

Review the genetic causes of FHI.

Goal 3.

Provide an evaluation strategy to identify the genetic cause of FHI in a proband (when possible).

Goal 4.

Inform (when possible) medical management of FHI based on genetic cause and evaluation of relatives at risk.

Goal 5.

Inform risk assessment and surveillance of at-risk relatives for early detection and treatment of FHI.

Familial Hyperinsulinism

Summary

Goal 1.

Goal 2.

Goal 3.

Goal 4.

Goal 5.

Diagnosis

Clinical Characteristics

Differential Diagnosis

Management